Table 1 Clinical characteristics, and treatment of patients with COVID-19 in the Adult Intensive Care Department of the Hospital de Clínicas during the first and the second waves of COVID-19 between August 2020 and August 2021. San Lorenzo. Paraguay (n=214)
Variable | Total n = 214 | Remdesivir n = 109 | No Remdesivir n = 105 | OR (CI 95%) | P |
|---|---|---|---|---|---|
Male sex, n (%) | 124 (57,9) | 58 (53,2) | 66 (62,9) | 0.672 (0.389-1.160) | 0,153 |
Age (years), mean ± SD | 53,10±13,11 | 52,23±13,1 | 54,2±13,0 | 0,001 | |
Vaccinated patients | 8 (3,7) | 3 (2,7) | 5 (4,7) | 0.566 (0.131-2.430) | 0.340 |
Comorbidities | |||||
Hypertension, n (%) | 107 (50) | 55 (50,5) | 52 (49,5) | 10.3 (0.607-1.774) | 0,891 |
Obesity, n (%) | 102 (47,7) | 60 (55,0) | 42 (40,0) | 1.837 (1.067-3.161) | 0,028 |
Diabetes mellitus, n (%) | 56 (26,2) | 24 (22,0) | 32 (30,5) | 0.644 (0.348-1.191) | 0,159 |
Chronic renal failure, n (%) | 12 (5,6) | 5 (4,6) | 7 (6,7) | 0.673 (0.207-2.191) | 0,509 |
Cardiac disease, n (%) | 12 (5,6) | 7 (6,4) | 5 (4,8) | 1.372 (0.422-4.468) | 0,598 |
Severity Score | |||||
APACHE II, median (IQR) | 12 (8) | 10 (6) | 13 (9) | <0.001 | |
SOFA initial, median (IQR) | 4 (5) | 3 (3) | 4 (5) | <0.001 | |
Treatment | |||||
Corticosteroid therapy | 183 (85,5) | 93 (85,3) | 90 (85,7) | 0.969 (0.452-2.075) | 0,935 |
Anticoagulation | |||||
Prophylaxis | 42 (19,6) | 22 (20,1) | 20 (19) | 1.075 (0.547-2.11) | 0.834 |
Therapeutic | 154 (72,0) | 77 (70,6) | 77 (70,6) | 0.875 (0.481-1.590) | 0,661 |
Convalescent plasma | 48 (22,4) | 31 (28,4) | 17 (16,2) | 2.05 (1.058-4.002) | 0,032 |
Tocilizumab | 20 (9,3) | 9 (8,3) | 11 (10,5) | 0.769 (0.305-1.939) | 0,577 |